Compared to those who did not use DEX, glioma patients who used DEX were also more likely to have a CD4 count < 200, CD4 count < 500, ANC ≥ 8870, ALC < 1000, total cell count ≥ 10,000 and an NLR ≥ 4 (all p < 0.001, Supplemental Table 4). The gene discussed is CD4; the disease is central nervous system cancer.